244 related articles for article (PubMed ID: 29164397)
21. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
22. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
23. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
[TBL] [Abstract][Full Text] [Related]
24. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
Huang F; Brezden-Masley C; Chan KKW; Barfett JJ; Kirpalani A; Deva DP; Jimenez-Juan L; Barthur A; Song L; Chacko B; Ng MY; Connelly K; Wong KCK; Yan AT
Eur Radiol; 2022 Jun; 32(6):4234-4242. PubMed ID: 34993574
[TBL] [Abstract][Full Text] [Related]
26. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
[TBL] [Abstract][Full Text] [Related]
28. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
29. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
[TBL] [Abstract][Full Text] [Related]
31. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.
Bian SX; Korah MP; Whitaker TR; Ji L; Groshen S; Chung E
Clin Breast Cancer; 2017 Nov; 17(7):510-515. PubMed ID: 28412326
[TBL] [Abstract][Full Text] [Related]
32. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
33. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
[TBL] [Abstract][Full Text] [Related]
34. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.
Abu-Khalaf MM; Safonov A; Stratton J; Wang S; Hatzis C; Park E; Pusztai L; Gross CP; Russell R
Breast Cancer Res Treat; 2019 Jul; 176(2):261-270. PubMed ID: 31020471
[TBL] [Abstract][Full Text] [Related]
35. The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Bouwer NI; Steenbruggen TG; Rier HN; Kitzen JJEM; Smorenburg CH; van Bekkum ML; de Jong PC; Drooger JC; Holterhues C; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
Int J Cancer; 2022 Aug; 151(4):616-622. PubMed ID: 35403708
[TBL] [Abstract][Full Text] [Related]
36. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
37. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
[TBL] [Abstract][Full Text] [Related]
38. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity Assessment After Different Adjuvant Hypofractionated Radiotherapy Concurrently Associated with Trastuzumab in Early Breast Cancer.
Bonzano E; Guenzi M; Corvò R
In Vivo; 2018; 32(4):879-882. PubMed ID: 29936473
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients.
Toukabri I; Ben Said A; Hamdi A; Aloulou A; Ben Ayed W; Cherif I; Limayem I
J Oncol Pharm Pract; 2023 Apr; 29(3):613-618. PubMed ID: 35088630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
